FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases

Charest, Mathieu; Hickeson, Marc; Lisbona, Robert; Novales-Diaz, Javier-A.; Derbekyan, Vilma; Turcotte, Robert

doi:10.1007/s00259-009-1203-0

Cited by 171 publications

(127 citation statements)

References 15 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…The SUVmax, MTV, and TLG were demonstrated to be prognostic factors for predicting OS. In previous reports, the SUVmax on pretreatment 18 F-FDG PET/CT could be used to discriminate between low-and high-grade soft tissue sarcomas [37,38]. In this study, pathologic tumor responder and non-responder groups were discriminated not only by the SUVmax, but also by MTV and TLG.…”

Section: Discussionmentioning

confidence: 71%

The Role of 18F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma

Chang

Lim

Park

et al. 2014

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose This research aims to investigate the potential of 18 Ffluorodeoxyglucose positron emission tomography/computed tomography (FDG PET) to predict pathologic response after neoadjuvant chemotherapy (NAC) and overall survival (OS) of patients with synovial sarcoma in Korea. Methods Twenty patients with synovial sarcoma from January 2001 to December 2011 were reviewed retrospectively. All patients underwent pre-treatment FDG PET and tumor removal. Patients were classified with the maximum SUV (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), age, sex, histologic subtype, tumor size, NAC, resection margin, and metastasis at diagnosis. Pathologic response was assessed using the French Federation of Cancer Centers system. Statistical analyses were analyzed using the Kaplan-Meier method, log-rank test, Cox proportional hazards regression model, and Mann-Whitney test. Results Nine patients (45 %) showed pathologic response, and ten patients survived. Higher SUVmax, higher MTV, higher TLG, monophasic epithelial type, and metastasis at diagnosis were significantly related to poorer OS (p=0.047, 0.016, 0.016, 0.045, and 0.018, respectively). By multivariate analysis, metastasis at diagnosis was significantly related to poorer OS (p=0.012/HR=5.9, 95 % CI 1.47 to 24.1). The SUVmax, MTV, and TLG of the non-responder group were significantly higher than those of the responder group (p= 0.020, 0.020, and 0.020, respectively). There was no significant difference in size between the two groups (p=0.062). Conclusions A higher SUVmax on the pre-treatment scan, monophasic epithelial type, and metastasis at diagnosis were significantly associated with a poorer OS, and pathologic responders showed a higher SUVmax before NAC. The PET parameters can be used to predict OS and pathologic response in patients with synovial sarcomas before NAC.

show abstract

Section: Discussionmentioning

confidence: 71%

The Role of 18F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma

Chang

Lim

Park

et al. 2014

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…A review of 212 patients of sarcomas (both osseous and softtissue sarcomas) revealed the mean SUVmax value of the primary and/or the most avid metastatic lesion in the positive cases to range from 5.6 to 23.2 (median, 9.9), with most lesions having an SUVmax .2.5. 29 Another study of 109 patients revealed SUVmax of the primary tumour to range from 1.7 to 35.8 (median, 7.7). 30 The definite role of PET/CT needs further clarification but mainly lies in evaluating patients for metastases, for assessing response to treatment and in detecting recurrent disease.…”

Section: Resultsmentioning

confidence: 99%

Imaging features of primary and metastatic alveolar soft part sarcoma: single institute experience in 25 patients

Sood¹,

Baheti²,

Shinagare³

et al. 2014

BJR

View full text Add to dashboard Cite

Objective: To describe imaging features of primary and metastatic alveolar soft part sarcoma (ASPS). Methods: In this institutional review board-approved and Health Insurance Portability and Accountability Actcompliant retrospective study, 25 patients (14 males; mean age, 25 years; range, 18-40 years) with pathologically proven ASPS seen at our institute between 1995 and 2013 were included. Imaging of primary tumours in 5 patients and follow-up imaging in 25 patients were reviewed by 2 radiologists in consensus. Clinical information was obtained from electronic medical records. Results: The most common sites for the primary tumour were extremities (17/25, 68%) and torso (6/25, 24%). Primary tumours (n 5 5) were well circumscribed, compared with skeletal muscle, were isodense on CT, hyperintense on T 1 and T 2 weighted images with intense post-contrast enhancement, prominent feeders on CT and flow voids on MRI. Metastases developed in 23/25 (92%) patients, 18 at presentation. The most common sites of metastases were the lungs (100%), lymph nodes (74%), bones (57%) and brain (43%). Visceral and nodal metastases were hypervascular. At the time of reporting the results, 15 patients have died, 6 are alive and 4 were lost to follow-up. Median survival was 74 months for those without brain metastases (n 5 8) and 60 months for those with brain metastases (n 5 7). Median survival was shorter for patients with metastases at presentation. Conclusion: ASPS most commonly involves the lower extremities of young adults, is hypervascular on imaging, often metastasizes at presentation, frequently to lung, nodes, bones and brain, and has an indolent course despite metastases. Brain metastases and high tumour burden (number of metastatic sites) at presentation decreased survival in our study. Advances in knowledge: ASPS has an unusual pattern of metastases to the brain and nodes in addition to lung and bones. It has an indolent course despite metastases.

show abstract

“…Of the 1,310 articles screened, 16 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) were selected for the final analysis (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Positron emission tomography/computed tomography for osseous and soft tissue sarcomas: A systematic review of the literature and meta-analysis

Muheremu

Amudong

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. In order to elucidate the value of positron emission tomography (PET)/computed tomography (CT) in the clinical diagnosis and treatment of osseous and soft tissue malignancies, two authors independently searched the PubMed, Medline, Elsevier, Embase and Cochrane Library databases for literature published between January 2003 and February 2016, using the key words 'PET/CT', 'positron emission tomography/computed tomography', 'osseous sarcoma', 'bone tumor', 'soft tissue sarcoma' and 'neoadjuvant', to identify prospective and retrospective studies on the applicability of PET/CT on the clinical diagnosis of bone and soft tissue lesions, and evaluation of their response to neoadjuvant therapies. Data were independently extracted by the two authors and any disagreements were resolved by a third author when necessary. Extracted data were analyzed by Meta-Disc 1.6 software. As a result, 16 trials with a total of 883 patients and 2,214 lesions were included in the present study. The overall diagnostic accuracy of PET/CT exhibited a sensitivity and specificity of 0.90 (0.86-0.92) and 0.89 (0.85-0.92), respectively, and the effect of neoadjuvant therapy was assessed with a sensitivity and specificity of 0.79 (0.30-0.93) and 0.79 (0.69-0.89), respectively. Thus, it may be concluded from the present study that PET/CT is a reliable imaging method to be applied in the diagnosis and treatment of osseous and soft tissue malignancies.

show abstract

FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases

Abstract: The combined metabolic and morphological information of FDG PET/CT imaging allows high sensitivity for the detection of various sarcomas and accurate discrimination between newly diagnosed low-grade and high-grade sarcomas.

Cited by 171 publications

References 15 publications

The Role of 18F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma

The Role of 18F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma

Imaging features of primary and metastatic alveolar soft part sarcoma: single institute experience in 25 patients

Positron emission tomography/computed tomography for osseous and soft tissue sarcomas: A systematic review of the literature and meta-analysis

Contact Info

Product

Resources

About